

Attorney Docket No.: ISPH-0617
Inventors: Bennett et al.
Serial No.: 10/001,844
Filing Date: November 16, 2001
Page 5

REMARKS

Claims 1, 5-10 and 12-15 are pending in the instant application. All of the claims have been rejected. Claim 1 has been amended. No new matter has been added by this amendment. Reconsideration is respectfully requested in light of the amendment and the following remarks.

I. Rejection of Claims Under 35 U.S.C. 112, paragraph 1

Claim 1, and by dependency claims 5-10 and 12-15 have been rejected under 35 U.S.C. 112, paragraph 1 for failing to comply with the written description requirement by containing new matter. The Examiner states that there is no support for the limitation of nucleotides targeted to nucleobases 501 through 926 of a nucleotide encoding Sonic Hedgehog (SHH) of SEQ ID NO:3.

Applicants have amended the claims to refer to antisense compounds that are targeted to nucleobases 666 through 685 of SEQ ID NO:3. Support for this amendment can be found on page 82 near the middle of Table 1, exemplified by ISIS No 104350. Therefore the rejection of claim 1, and by dependency claims 5-10 and 12-15 is traversed.

Attorney Docket No.: ISPH-0617
Inventors: Bennett et al.
Serial No.: 10/001,844
Filing Date: November 16, 2001
Page 6

III. Conclusion

Applicants believe that the foregoing comprises a full and complete response to the Office Action of record. Accordingly, favorable reconsideration and subsequent allowance of the pending claims is earnestly solicited.
Respectfully submitted,



Colleen J. McKiernan, PhD
Registration No. 48,570

Date: December 21, 2004

Isis Pharmaceuticals
2922 Faraday Avenue
Carlsbad, CA 92008

Phone: 760-603-2722
Facsimile: 760-603-3820